Results 1 to 10 of about 123,267 (281)

Factor IX and thrombosis [PDF]

open access: yesBritish Journal of Haematology, 2001
No abstract available.
Lowe, G.D.O.
openaire   +4 more sources

Activation of Factor IX by Factor XIa - A Spectrophotometric Assay for Factor IX in Human Plasma [PDF]

open access: yesThrombosis and Haemostasis, 1982
SummaryThe activation of Factor IX by partially purified Factor XIa was followed by active site titration, gelelectrophoresis and by a spectrophotometric assay. The assay is based on the finding that the rate of Factor X activation in the presence of phospholipid and Ca2+ is linear in time and proportional to the amount of Factor IXa present and can be
Tans, G.   +4 more
openaire   +3 more sources

Successful immunosuppressive drug‐free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report [PDF]

open access: yesClinical Case Reports
Key Clinical Message Recommendations advise factor IX desensitization before immune tolerance induction in severe hemophilia B, supported by immunosuppression.
Ángeles Palomo Bravo   +4 more
doaj   +2 more sources

X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) [PDF]

open access: yesNew England Journal of Medicine, 2009
We report a case of juvenile thrombophilia associated with a substitution of leucine for arginine at position 338 (R338L) in the factor IX gene (factor IX-R338L). The level of the mutant factor IX protein in plasma was normal, but the clotting activity of factor IX from the proband was approximately eight times the normal level.
SIMIONI, PAOLO   +9 more
openaire   +4 more sources

A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B [PDF]

open access: yesJournal of Blood Medicine
Zoran Igrutinović,1,2 Hélène Louise Hooimeijer,3 Karim Kentouche,4 Jaco Botha,5 Peter L Turecek,6 Marta Kokot-Kierepa,5 Hanna T Gazda7 1Clinic of Pediatrics, Department of Hemato-Oncology, University Clinical Center of Kragujevac, Kragujevac ...
Igrutinović Z   +6 more
doaj   +2 more sources

Peri-operative Management and the Role of Minimally Invasive Spine Surgery in a Case of Hemophilia B [PDF]

open access: yesJournal of Minimally Invasive Spine Surgery and Technique, 2022
Hemophilia A and B are rare X-chromosome-linked recessive bleeding disorders caused by mutations in the genes causing abnormalities of blood clotting factors VIII and IX, respectively.
VNR Praveen Goparaju   +3 more
doaj   +1 more source

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)

open access: yesTH Open, 2022
In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term ...
Tine M.H.J. Goedhart   +13 more
doaj   +1 more source

The Liver That Cured Christmas: Case Report of Orthotopic Liver Transplant in a Patient with Hemophilia B

open access: yesCase Reports in Transplantation, 2020
Herein, we discuss a case of a 39-year-old male with hemophilia B, who developed end-stage liver disease secondary to nonalcoholic steatohepatitis, that underwent orthotopic liver transplantation (OLT) as a curative means for his liver disease and ...
Jesse E. Harris   +3 more
doaj   +1 more source

A Case of Heel Reconstruction with a Reverse Sural Artery Flap in a Hemophilia B Patient

open access: yesArchives of Plastic Surgery, 2012
Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing.
Byung Kwon Lee, Jeong Su Shim
doaj   +1 more source

Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs

open access: yesMolecular Therapy: Methods & Clinical Development, 2019
Gene therapy for severe hemophilia B is advancing and offers sustained disease amelioration with a single treatment. We have reported the efficacy and safety of AMT-060, an investigational gene therapy comprising an adeno-associated virus serotype 5 ...
Elisabeth A. Spronck   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy